非移植的费城染色体阳性急性淋巴细胞白血病患者停用酪氨酸激酶抑制剂：一项校园ALL真实世界研究 - Suppr

Tyrosine kinase inhibitor discontinuation in nonallografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study.

作者信息

Dragani Matteo, Ansuinelli Michela, Papayannidis Cristina, Fracchiolla Nicola, Cardinali Valeria, Cedrone Michele, Guolo Fabio, Perrone Salvatore, Salutari Prassede, Todisco Elisabetta, Foà Robin, Chiaretti Sabina

机构信息

Hematology and Cellular Therapy, IRCCS Ospedale Policlinico San Martino.

Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome.

出版信息

Haematologica. 2025 May 1;110(5):1177-1181. doi: 10.3324/haematol.2024.286325. Epub 2025 Jan 9.

DOI:10.3324/haematol.2024.286325

PMID:39781617

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12050923/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6fcd/12050923/30c9f556737c/1101177.fig1.jpg

相似文献

Tyrosine kinase inhibitor discontinuation in nonallografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study.

Haematologica. 2025 May 1;110(5):1177-1181. doi: 10.3324/haematol.2024.286325. Epub 2025 Jan 9.

The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia.

Cancer Med. 2024 Sep;13(17):e70161. doi: 10.1002/cam4.70161.

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

Clin Ther. 2007 Nov;29(11):2289-308. doi: 10.1016/j.clinthera.2007.11.005.

Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.

Acta Haematol. 2021;144(3):285-292. doi: 10.1159/000510112. Epub 2020 Nov 25.

Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.

Haematologica. 2015 Mar;100(3):392-9. doi: 10.3324/haematol.2014.116954. Epub 2014 Dec 19.

Ponatinib for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Drugs Today (Barc). 2013 Apr;49(4):261-9. doi: 10.1358/dot.2013.49.4.1950147.

Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.

J Hematol Oncol. 2016 Apr 18;9:40. doi: 10.1186/s13045-016-0270-5.

Improvement of Bone Marrow Necrosis by Tyrosine Kinase Inhibitor Substitution in a Pediatric Patient With Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia.

J Pediatr Hematol Oncol. 2022 Mar 1;44(2):e539-e542. doi: 10.1097/MPH.0000000000002157.

Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.

Med Oncol. 2010 Dec;27(4):1123-6. doi: 10.1007/s12032-009-9347-0. Epub 2009 Nov 3.

Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Haematologica. 2015 May;100(5):653-61. doi: 10.3324/haematol.2014.118588. Epub 2015 Feb 14.

引用本文的文献

Treatment-Free Remission in Ph+ ALL Without Allogeneic Stem Cell Transplantation: Current Evidence and Future Directions.

Cancers (Basel). 2025 Jul 25;17(15):2457. doi: 10.3390/cancers17152457.

本文引用的文献

Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.

J Clin Oncol. 2024 Sep 10;42(26):3140-3150. doi: 10.1200/JCO.24.00108. Epub 2024 Jul 19.

Long-Term Results of the Dasatinib-Blinatumomab Protocol for Adult Philadelphia-Positive ALL.

J Clin Oncol. 2024 Mar 10;42(8):881-885. doi: 10.1200/JCO.23.01075. Epub 2023 Dec 21.

Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT-PCR for BCR::ABL1.

Am J Hematol. 2023 Aug;98(8):1196-1203. doi: 10.1002/ajh.26949. Epub 2023 May 15.

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.

Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16.

Minimal residual disease in BCR::ABL1-positive acute lymphoblastic leukemia: different significance in typical ALL and in CML-like disease.

Leukemia. 2022 Dec;36(12):2793-2801. doi: 10.1038/s41375-022-01668-0. Epub 2022 Aug 6.

Applicability of droplet digital polymerase chain reaction for minimal residual disease monitoring in Philadelphia-positive acute lymphoblastic leukaemia.

Hematol Oncol. 2021 Dec;39(5):680-686. doi: 10.1002/hon.2913. Epub 2021 Aug 16.

Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.

Blood. 2021 Dec 2;138(22):2290-2293. doi: 10.1182/blood.2021011822.

Discontinuation of Maintenance Tyrosine Kinase Inhibitors in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia outside of Transplant.

Acta Haematol. 2021;144(3):285-292. doi: 10.1159/000510112. Epub 2020 Nov 25.

Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.

Cancer. 2021 Mar 15;127(6):905-913. doi: 10.1002/cncr.33321. Epub 2020 Nov 24.

Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.

N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Tyrosine kinase inhibitor discontinuation in nonallografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study.

作者信息

机构信息

Hematology and Cellular Therapy, IRCCS Ospedale Policlinico San Martino.

Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome.

出版信息

Haematologica. 2025 May 1;110(5):1177-1181. doi: 10.3324/haematol.2024.286325. Epub 2025 Jan 9.

DOI:10.3324/haematol.2024.286325

PMID:39781617

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12050923/

Abstract

摘要

Tyrosine kinase inhibitor discontinuation in nonallografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Tyrosine kinase inhibitor discontinuation in nonallografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

本文引用的文献